Menopause & Hormonal Health and Platelet-rich plasma (PRP): what the trial registry contains
The ClinicalTrials.gov registry holds 13 records for PRP in Menopause & Hormonal Health: 2 recruiting now, 2 labelled Phase 3 or 4, across 10 countries. Snapshot 2026-08-29.
Why this is studied in Menopause & Hormonal Health
Menopause is a physiological transition, not a disease, and registry entries here mostly concern ovarian function and menopausal symptoms rather than reversal of the transition. The commercial framing of 'ovarian rejuvenation' runs far ahead of what registered studies attempt.
What PRP means in this table
Platelet-rich plasma is a blood product, not a stem-cell product, though it is routinely sold as part of the same package. Preparation varies enormously between systems — platelet concentration, leukocyte content and activation all differ — so the label describes a category of procedure rather than a defined substance, which is the main reason its trial literature is so inconsistent.
The numbers
Every figure below comes from one reproducible query (menopause x platelet-rich plasma) run against ClinicalTrials.gov API v2 on 2026-08-29.
| Metric | Value |
|---|---|
| Registered studies (all statuses) | 13 |
| Interventional studies in the sample | 12 |
| Recruiting right now | 2 |
| Completed | 5 |
| Terminated, withdrawn or suspended | 0 |
| Phase 3 or Phase 4 records | 2 |
| Countries with at least one site | 10 |
| Median planned enrolment | 45 participants |
| Largest single planned enrolment | 200 participants |
| First / most recent start year | 2017 — 2025 |
How mature is this evidence?
The field has produced some later-stage designs — 2 of the 13 records carry a Phase 3 or 4 label — but the bulk of activity remains earlier-phase safety and signal-finding work.
The delivery record matters as much as the count: 5 completed against 0 abandoned or suspended, or 0% of everything registered.
| Phase label | Records | Share |
|---|---|---|
| Phase 1 | 5 | 31% |
| Not applicable | 5 | 31% |
| Phase 2 | 4 | 25% |
| Phase 3 | 1 | 6% |
| Phase 4 | 1 | 6% |
Median planned enrolment is 45 participants (largest single study: 200). Trials of this size can describe safety and generate hypotheses; detecting a modest clinical benefit reliably usually needs substantially larger numbers with a control group.
Where the studies are
Sites are spread across 10 countries, with United States accounting for roughly 40% of country mentions — geography reflects where regulators permit this work and where sponsors sit, not where care is best.
| Country | Studies with a site there |
|---|---|
| United States | 6 |
| Malta | 1 |
| North Macedonia | 1 |
| Serbia | 1 |
| Taiwan | 1 |
| Greece | 1 |
| Spain | 1 |
| Turkey (Türkiye) | 1 |
| Egypt | 1 |
| Portugal | 1 |
Legal pathway differs by country — see where cell therapy is legal, by country.
Who runs them
Sponsorship leans commercial: 1 of the most frequent lead sponsors read as academic or hospital entities and 5 as companies. Who pays shapes what gets measured and what gets published.
- Forever Young d.o.o. — 1 record
- Mackay Memorial Hospital — 1 record
- Genesis Athens Clinic — 1 record
- Center for Human Reproduction — 1 record
- Mayo Clinic — 1 record
- Fundación Santiago Dexeus Font — 1 record
Representative registered studies
Recruiting studies first, then the most advanced phases. Each identifier links to the registry record, where eligibility criteria, outcome measures and contacts are published.
| Study | Phase | Status | Planned n | Lead sponsor | Start |
|---|---|---|---|---|---|
| NCT06425978 — Efficacy of the Use of Cellular Matrix/ A-CP-HA Kit | Phase 4 | Recruiting | 192 | Fundación Santiago Dexeus Font | 2024-05-30 |
| NCT04031456 — Autologous PRP Infusion May Restore Ovarian Function and May Promote Folliculogenesis in POI Patients | Phase 2, Phase 3 | Recruiting | 100 | Genesis Athens Clinic | 2019-07-30 |
| NCT05812924 — A Novel Therapy for Breast Cancer Survivors With Genitourinary Syndrome of Menopause | Phase 2 | Active Not Recruiting | 18 | University of Miami | 2023-09-26 |
| NCT06028009 — PRP Injections for Genitourinary Syndrome of Menopause | n/a | Active Not Recruiting | 30 | Medstar Health Research Institute | 2024-03-01 |
| NCT07306611 — Regenerative Treatment of Female Genital Atrophy | Phase 1, Phase 2 | Completed | 30 | AndreiaAntunes | 2024-06-04 |
| NCT04009473 — Stem Cell Therapy and Growth Factor Ovarian in Vitro Activation | Phase 1, Phase 2 | Unknown | 100 | Forever Young d.o.o. | 2019-06-01 |
| NCT04444245 — Ovarian Rejuvenation Using Platelet Rich Plasma (PRP) & Autologous Tissue Stromal Vascular Fraction (tSVF) and Cell Enriched tSVF | Phase 1 | Unknown | 100 | Black Tie Medical, Inc. | 2022-07-15 |
| NCT04535323 — Platelet Rich Plasma for the Treatment of Genitourinary Syndrome of Menopause in Patients With Stage 0-III Breast Cancer | Phase 1 | Completed | 20 | Mayo Clinic | 2020-09-23 |
| NCT03178695 — Inovium Ovarian Rejuvenation Trials | Phase 1 | Completed | 200 | Ascendance Biomedical | 2017-06-01 |
| NCT05483634 — Compare Vaginal Estrogen and Platelet-rich Plasma Over Women With Genitourinary Syndrome of Menopause | n/a | Not Yet Recruiting | 40 | Mackay Memorial Hospital | 2025-12-01 |
What this page does and does not tell you
These figures describe effort, not outcome. Published results, with their control arms and endpoints, are where benefit is decided.
If a clinic offers you this today, the useful question is not "is there research?" but "which of these registered studies is mine part of, and if none, what evidence applies to the exact product I am being sold?" The Provider Question Builder turns that into a scored checklist.
Frequently asked
How many PRP studies for Menopause & Hormonal Health are recruiting right now?
2 of 13 registered records were listed as recruiting in the 2026-08-29 snapshot. Recruitment status changes frequently; the registry record is authoritative.
Is PRP an approved treatment for Menopause & Hormonal Health?
Registration on ClinicalTrials.gov is not approval. Approval is granted by a regulator for a specific product and indication after review of submitted evidence. 13 registered studies tell you research exists, not that a product cleared review.
How advanced is the research on PRP for Menopause & Hormonal Health?
2 of 13 records carry a Phase 3 or Phase 4 label and 5 are marked completed. Registrations run from 2017 to 2025.
Registry and literature counts retrieved 2026-08-29 (ClinicalTrials.gov API v2; PubMed E-utilities). Registration or publication volume measures research activity, not effectiveness or approval. Educational information — not medical advice; verify product, indication, legal pathway and evidence with an independent qualified physician. Page generated 2026-08-29. See our editorial standards.
More on this condition
Download the query data
Query totals are full API matches; status, phase and country counts describe the first up to 400 returned records per query. Query classes overlap and must not be summed as unique trials. Counts are not treatment outcomes. Snapshot: 2026-08-29. Methods and field definitions.